scholarly journals Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection

2021 ◽  
Author(s):  
Benjamin Taubner ◽  
Ruben Peredo-Wende ◽  
Ananthakrishnan Ramani ◽  
Gurpreet Singh ◽  
Klemen Strle ◽  
...  
Keyword(s):  
Immune Response ◽  
Quantitative Detection ◽  
Human Antibodies ◽  
Biosensor Technology ◽  
Novel Coronavirus ◽  
Antibody Levels

In this work, a novel biosensor technology was used to measure antibody levels that resulted from vaccination against COVID-19 and/or from infection with the virus. Importantly, this approach enables quantification of antibody levels, which can provide information about the timing and level of immune response.

scholarly journals Rapid and Quantitative Detection of Human Antibodies Against the 2019 Novel Coronavirus SARS CoV2 and its Variants as a Result of Vaccination and Infection

2021 ◽  
Author(s):  
Benjamin Taubner ◽  
Ruben Peredo-Wende ◽  
Ananthakrishnan Ramani ◽  
Gurpreet Singh ◽  
Klemen Strle ◽  
...  
Keyword(s):  
Accurate Method ◽  
Competitive Elisa ◽  
Antibody Binding ◽  
Quantitative Detection ◽  
Elisa Assay ◽  
Serological Response ◽  
N Protein ◽  
Human Antibodies ◽  
Novel Coronavirus ◽  
Antibody Levels

Measuring the antibody response to 2019 SARS CoV2 is critical for diagnostic purposes, monitoring the prevalence of infection, and for gauging the efficacy of the worldwide vaccination effort COVID-19. In this study, a microchip-based grating coupled fluorescent plasmonic (GC-FP) assay was used to measure antibody levels that resulted from COVID-19 infection and vaccination. In addition, we measured the relative antibody binding towards antigens from variants CoV2 virus variants, strains B.1.1.7 (UK) and B.1.351 (S. African). Antibody levels against multiple antigens within the SARS CoV2 spike protein were significantly elevated for both vaccinated and infected individuals, while those against the nucleocapsid (N) protein were only elevated for infected individuals. GC-FP was effective for monitoring the IgG-based serological response to vaccination throughout the vaccination sequence, and could also resolve acute (within hours) increases in antibody levels. A significant decrease in antibody binding to antigens from the B.1.351 variant, but not B.1.1.7, was observed for all vaccinated subjects when measured by GC-FP as compared to the 2019 SARS CoV2 antigens. These results were corroborated by competitive ELISA assay. Collectively, the findings suggest that GC-FP is a viable, rapid, and accurate method for measuring both overall antibody levels to CoV2 and relative antibody binding to viral variants during infection or vaccination.

scholarly journals Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0247797
Author(s):  
Renee L. Higgins ◽  
Stephen A. Rawlings ◽  
Jamie Case ◽  
Florence Y. Lee ◽  
Clarence W. Chan ◽  
...  
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Vaccine Development ◽  
Treatment Strategies ◽  
Lateral Flow ◽  
Patient Specific ◽  
The Novel ◽  
Successful Vaccine ◽  
Novel Coronavirus ◽  
Antibody Levels

Since the initial identification of the novel coronavirus SARS-CoV-2 in December of 2019, researchers have raced to understand its pathogenesis and begun devising vaccine and treatment strategies. An accurate understanding of the body’s temporal immune response against SARS-CoV-2 is paramount to successful vaccine development and disease progression monitoring. To provide insight into the antibody response against SARS-CoV-2, plasma samples from 181 PCR-confirmed COVID-19 patients collected at various timepoints post-symptom onset (PSO) were tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies via lateral flow. Additionally, 21 donors were tracked over time to elucidate patient-specific immune responses. We found sustained levels of anti-SARS-CoV-2 antibodies past 130 days PSO, with 99% positivity observed at 31–60 days PSO. By 61–90 days PSO, the percentage of IgM-/IgG+ results were nearly equal to that of IgM+/IgG+ results, demonstrating a shift in the immune response with a decrease in IgM antibody levels. Results from this study not only provide evidence that the antibody response to COVID-19 can persist for over 4 months, but also demonstrates the ability of Easy Check™ to monitor seroconversion and antibody response of patients. Easy Check was sufficiently sensitive to detect antibodies in patient samples as early as 1–4 days PSO with 86% positivity observed at 5–7 days PSO. Further studies are required to determine the longevity and efficacy of anti-SARS-CoV-2 antibodies, and whether they are protective against re-infection.

scholarly journals Characterization of the Diagnostic Performance of a Novel COVID-19 PETIA in Comparison to Four Routine N-, S- and RBD-Antigen Based Immunoassays

Diagnostics ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1332
Author(s):  
Alexander Spaeth ◽  
Thomas Masetto ◽  
Jessica Brehm ◽  
Leoni Wey ◽  
Christian Kochem ◽  
...  
Keyword(s):  
Immune Response ◽  
Cross Reactivity ◽  
Enzyme Linked Immunosorbent Assay ◽  
Chemiluminescence Immunoassay ◽  
Face To Face ◽  
Comprehensive Comparison ◽  
Broad Variety ◽  
Viral Responses ◽  
Novel Coronavirus ◽  
High Consistency

In 2019, a novel coronavirus emerged in Wuhan in the province of Hubei, China. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quickly spread across the globe, causing the neoteric COVID-19 pandemic. SARS-CoV-2 is commonly transmitted by droplet infection and aerosols when coughing or sneezing, as well as high-risk exposures to infected individuals by face-to-face contact without protective gear. To date, a broad variety of techniques have emerged to assess and quantify the specific antibody response of a patient towards a SARS-CoV-2 infection. Here, we report the first comprehensive comparison of five different assay systems: Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Electro-Chemiluminescence Immunoassay (ECLIA), and a new Particle-Enhanced Turbidimetric Immunoassay (PETIA) for SARS-CoV-2. Furthermore, we also evaluated the suitability of N-, S1- and RBD-antigens for quantifying the SARS-CoV-2 specific immune response. Linearity and precision, overall sensitivity and specificity of the assays, stability of samples, and cross-reactivity of general viral responses, as well as common coronaviruses, were assessed. Moreover, the reactivity of all tests to seroconversion and different sample matrices was quantified. All five assays showed good overall agreement, with 76% and 87% similarity for negative and positive samples, respectively. In conclusion, all evaluated methods showed a high consistency of results and suitability for the robust quantification of the SARS-CoV-2-derived immune response.

scholarly journals Maternally Derived Antibody Levels Influence on Vaccine Protection against PCV2d Challenge

Animals ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 2231
Author(s):  
István Kiss ◽  
Krisztina Szigeti ◽  
Zalán G. Homonnay ◽  
Vivien Tamás ◽  
Han Smits ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Subunit Vaccine ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus ◽  
Vaccine Protection ◽  
Humoral Immune ◽  
Negative Effect ◽  
Antibody Levels

Piglets from a porcine circovirus type 2 (PCV2) stable farm of low and high levels of maternally derived antibodies (MDA) against PCV2 were vaccinated either with a whole virus type or a PCV2 ORF2 antigen-based commercial subunit vaccine at three weeks of age. Two non-vaccinated groups served as low and high MDA positive controls. At four weeks post vaccination, all piglets were challenged with a PCV2d-2 type virus strain and were checked for parameters related to vaccine protection over a four-week observation period. MDA levels evidently impacted the outcome of the PCV2d-2 challenge in non-vaccinated animals, while it did not have a significant effect on vaccine-induced protection levels. The humoral immune response developed faster in the whole virus vaccinates than in the subunit vaccinated pigs in the low MDA groups. Further, high MDA levels elicited a stronger negative effect on the vaccine-induced humoral immune response for the subunit vaccine than for the whole virus vaccine. The group-based oral fluid samples and the group mean viraemia and faecal shedding data correlated well, enabling this simple, and animal welfare-friendly sampling method for the evaluation of the PCV2 viral load status of these nursery piglets.

22. Immune Response to Stenotrophomonas maltophilia in Cystic Fibrosis Patients

2018 ◽  
Author(s):  
Jillian Wettlaufer
Keyword(s):  
Cystic Fibrosis ◽  
Immune Response ◽  
Clinical Outcomes ◽  
Optical Density ◽  
Stenotrophomonas Maltophilia ◽  
Negative Control ◽  
Chronic Patients ◽  
Significant Difference ◽  
Antibody Levels ◽  
Sera Samples

Background: Stenotrophomonas maltophilia is one of the most common multidrug-resistant organisms isolated from the cystic fibrosis (CF) respiratory tract but it is unknown how it influences the long term clinical outcomes of CF patients.   Objective/Hypothesis: To characterize the immune response to S. maltophilia and its association with clinical outcomes in CF patients over time.  Methods: This was a longitudinal study from 2007-2014 of CF patients followed at The Hospital for Sick Children and St. Michael’s Hospital. All patients were classified as: 1) those with chronic S. maltophilia: ³2 positive cultures/year, 2) intermittent S. maltophilia: 1 positive sputum culture/year, and 3) no S. maltophilia cultures/year with and without chronic P. aeruginosa. IgG/IgA/IgM serologic responses were measured in serial sera samples by ELISA using whole cell S. maltophilia antigen. Results were calculated as the ratio of the average serum sample optical density to the average optical density of the negative control wells. Antibody levels for each patient were compared longitudinally to their rate of decline in FEV1 % predicted, body mass index, and rate of hospitalization.   Results: S. maltophilia antibody levels were measured in 350 sera samples from 113 CF patients. Median baseline antibody levels were 1.56 (range 0.996-5.15) in chronic patients, 1.09 (range 0.907-3.79) in intermittent patients, and 1.12 (range 0.737-4.86) in patients with no S. maltophilia.  Conclusions: Preliminary data suggests antibody levels to be significantly higher in patients with chronic S. maltophilia, and no significant difference between intermittent S. maltophilia and no S. maltophilia.

Immune-response against Streptococcus pyogenes in the development of abdominal aortic aneurysm – A population-based case-control study

VASA ◽  
2008 ◽  
Vol 37 (2) ◽  
pp. 143-149 ◽  
Author(s):  
Wanhainen ◽  
Rasmussen ◽  
Björck ◽  
Björck
Keyword(s):  
Immune Response ◽  
Abdominal Aortic Aneurysm ◽  
Streptococcus Pyogenes ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Abdominal Aortic ◽  
History Of ◽  
Antibody Levels ◽  
Control Study

Background: In a population-based case-control study the association between antibodies to Streptococcus pyogenes antigens and the development of abdominal aortic aneurysm (AAA) was analysed. Patients and methods: Forty-two patients with screening-detected AAA were compared to 100 age- and sex matched controls with normal aortas. Antibodies against three recently characterized cell wall-attached proteins of S. pyogenes (SclA, SclB and GRAB) were analysed in plasma samples obtained at screening (current), and in samples obtained from a study conducted 12 years previously on the same population (historical). Results: Historical antibody levels against the S. pyogenes antigen GRAB were significantly higher in AAA patients compared with controls (0.25 vs 0.17, p = 0.021). A similar trend was observed in current GRAB antibody levels (0.23 vs 0.17, p = 0.072). GRAB-antibody levels at age 60 years retained the association with AAA in a logistic regression model after adjustment for a history of atherosclerosis (OR 20.2, p = 0.022), current smoking (OR 21.4, p = 0.025) and family history of AAA (OR 12.9, p = 0.053). Current and historical antibody levels against SclA and SclB in AAA patients were similar to those in controls. Conclusions: The results indicate that the immune response against S. pyogenes protein GRAB may be involved in the pathogenesis of AAA.

scholarly journals Effects of Loigolactobacillus coryniformis K8 CECT 5711 on the Immune Response of Elderly Subjects to COVID-19 Vaccination: A Randomized Controlled Trial

Nutrients ◽  
2022 ◽  
Vol 14 (1) ◽  
pp. 228
Author(s):  
Anxo Fernández-Ferreiro ◽  
Francisco J. Formigo-Couceiro ◽  
Roi Veiga-Gutierrez ◽  
Jose A. Maldonado-Lobón ◽  
Ana M. Hermida-Cao ◽  
...  
Keyword(s):  
Immune Response ◽  
Controlled Trial ◽  
Severe Disease ◽  
Nursing Home Residents ◽  
Vaccination Schedule ◽  
Elderly Subjects ◽  
Double Blind ◽  
Iga Antibody ◽  
Specific Igg ◽  
Antibody Levels

Elderly people are particularly vulnerable to COVID-19, with a high risk of developing severe disease and a reduced immune response to the COVID-19 vaccine. A randomized, placebo-controlled, double-blind trial to assess the effect of the consumption of the probiotic Loigolactobacillus coryniformis K8 CECT 5711 on the immune response generated by the COVID-19 vaccine in an elderly population was performed. Two hundred nursing home residents >60 yrs that had not COVID-19 were randomized to receive L. coryniformis K8 or a placebo daily for 3 months. All volunteers received a complete vaccination schedule of a mRNA vaccine, starting the intervention ten days after the first dose. Specific IgG and IgA antibody levels were analyzed 56 days after the end of the immunization process. No differences between the groups were observed in the antibody levels. During the intervention, 19 subjects had COVID-19 (11 receiving K8 vs. 8 receiving placebo, p = 0.457). Subgroup analysis in these patients showed that levels of IgG were significantly higher in those receiving K8 compared to placebo (p = 0.038). Among subjects >85 yrs that did not get COVID-19, administration of K8 tended to increase the IgA levels (p = 0.082). The administration of K8 may enhance the specific immune response against COVID-19 and may improve the COVID-19 vaccine-specific responses in elderly populations.

scholarly journals Development of a Smartphone-Based Nanozyme-Linked Immunosorbent Assay for Quantitative Detection of SARS-CoV-2 Nucleocapsid Phosphoprotein in Blood

2021 ◽  
Vol 12 ◽  
Author(s):  
Bochao Liu ◽  
Ze Wu ◽  
Chaolan Liang ◽  
Jinhui Lu ◽  
Jinfeng Li ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Cross Reactivity ◽  
Quantitative Detection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Samples ◽  
Primary Screening ◽  
Global Pandemic ◽  
Novel Coronavirus ◽  
Acid Test ◽  
Control Samples

Since December 2019, a novel coronavirus (SARS-CoV-2) has resulted in a global pandemic of coronavirus disease (COVID-19). Although viral nucleic acid test (NAT) has been applied predominantly to detect SARS-CoV-2 RNA for confirmation diagnosis of COVID-19, an urgent need for alternative, rapid, and sensitive immunoassays is required for primary screening of virus. In this study, we developed a smartphone-based nanozyme-linked immunosorbent assay (SP-NLISA) for detecting the specific nucleocapsid phosphoprotein (NP) of SARS-CoV-2 in 37 serum samples from 20 COVID-19 patients who were diagnosed by NAT previously. By using SP-NLISA, 28/37 (75.7%) serum samples were detected for NP antigens and no cross-reactivity with blood donors’ control samples collected from different areas of China. In a control assay using the conventional enzyme-linked immunosorbent assay (ELISA), only 7/37 (18.91%) serum samples were detected for NP antigens and no cross-reactivity with control samples. SP-NLISA could be used for rapid detection of SARS-CoV-2 NP antigen in primary screening of SARS-CoV-2 infected individuals.

VACCINATION AS PRIMARY CONTACT WITH INFLUENZA A AND B VIRUSES

PEDIATRICS ◽  
1949 ◽  
Vol 3 (2) ◽  
pp. 208-213
Author(s):  
RAE V. NICHOLAS ◽  
WERNER HENLE
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Influenza A ◽  
Infectious Agents ◽  
Older Individuals ◽  
Protective Measures ◽  
Primary Contact ◽  
Small Doses ◽  
Antibody Levels ◽  
Booster Effect

A single dose of 0.5 ml. of commercially available influenzal virus vaccine injected into children from seven weeks to three years of age produced antibodies in about 70%. Resulting antibody levels in the children, most of whom were born after the last widespread epidemics of influenza A and B, were distinctly lower than those observed in older individuals who, in all likelihood, had experienced previous contacts with influenzal antigens. Two injections at a week's interval failed to result in a better antibody response in these children in agreement with the experience gained in adults. Increase in the dose of vaccine appears unwarranted now, since the incidence of febrile reactions—all of short duration—exceeded 40%. This inferior antibody response may be the result of several factors: (a) the smaller dose of vaccine which can be safely administered to such children; (b) the possible inferior immune response of the younger individual; and (c) the absence of a basic immunity to the antigens present in most older individuals as a result of previous contacts with influenzal viruses. Although it is impossible to decide among these factors, the booster effect of restimulation with small doses of antigen is a well known phenomenon in protective measures against other infectious agents. It is felt that such a mechanism may well be the explanation for the discrepancies between young children and older individuals in their response to vaccination against influenza.

scholarly journals Dynamics of humoral immune response in pregnant mares and foals vaccinated with Theileria equi recombinant EMA-2

2018 ◽  
Vol 38 (6) ◽  
pp. 1105-1109
Author(s):  
Alice C. Santos ◽  
Fábio P.L. Leite ◽  
Ana M. Vianna ◽  
Guilherme B. Weege ◽  
Ilusca S. Finger ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Fold Increase ◽  
Serum Levels ◽  
Vaccination Schedule ◽  
Theileria Equi ◽  
Humoral Immune ◽  
Baseline Values ◽  
Antibody Levels ◽  
First Time

ABSTRACT: Theileria equi is an infectious hemoprotozoan agent of equine piroplasmosis, a disease that has severe economic and sanitary impact internationally. In addition to its common clinical features, piroplasmosis can cause gestational losses and neonatal damage, which makes neonates susceptible to this disease. The aim of this study was to evaluate the dynamics of humoral immune response to recombinant EMA-2 of T. equi in pregnant mares and foals, as well as the transfer of vaccine antibodies through the colostrum ingested by sucking foals. For vaccine production, the EMA-2 expression gene was cloned and expressed in the yeast species, Pichia pastoris. Thirty-six horses were used, of which 18 were pregnant mares and 18 were foals. The mares were divided into control and vaccinated groups, and the vaccinated group received three doses of rEMA-2 every 21 days starting at 300 days of gestation. Foals from vaccinated and control groups were evaluated until the sixth month of life. The production of antibodies by foals on the rEMA-2 vaccination schedule was also evaluated from the second month of life. Foals in the vaccinated group had received three doses of the vaccine every 21 days. The method used to evaluate serum and colostrum samples was indirect ELISA, and plates were sensitized with the rEMA-2 protein. At the end of the vaccination schedule, vaccinated mares showed a 2.3-fold increase in antibody levels when compared to baseline values. The colostrum of vaccinated mares presented antibody levels of 1.0432±0.33. Foals delivered by vaccinated mares presented levels of antibodies greater than those of foals delivered by control mares after their first time sucking (at about twelve hours after birth). Foals vaccinated in the second month of life showed an 8.3-fold increase in antibody levels when compared to baseline values. The vaccination schedule with rEMA-2 was able to stimulate humoral immunity in pregnant mares. Vaccine immunoglobins were concentrated in the colostrum of vaccinated mares and foals delivered by these mares showed an increase in serum levels of vaccine antibodies after the first-time sucking.

Sign in / Sign up

Export Citation Format

Share Document